Design Therapeutics (DSGN)
(Delayed Data from NSDQ)
$5.29 USD
-0.12 (-2.22%)
Updated Aug 27, 2025 04:00 PM ET
After-Market: $5.30 +0.01 (0.19%) 5:44 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DSGN 5.29 -0.12(-2.22%)
Will DSGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DSGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DSGN
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why
Wall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High?
DSGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for DSGN
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference | DSGN Stock News
Stochastic Reached Overbought appears for DSGN after 4.04% move
The technical outlook for DSGN is unchanged after it falls 1.14% on August 25
NR7 appears for DSGN after 2.14% move
DSGN forms 180 Bullish Setup on August 21